---

Highlights of January 2023

Sun Pharma acquires U.S.-based Concert Pharma for $576 million, to gain access to its experimental drug for treating patchy baldness. Cipla invests 15 million Euros in Ethris for mRNA-based inhalation therapies. Sun Pharma acquires three anti-inflammation brands from Aksigen. Pathkind Labs, Roche Diagnostics partner to release cardiac biomarker. Dr Reddy's acquires trademark rights of breast cancer drug Primcyv from Pfizer to use in India. Mankind Pharma invests in Actimed Therapeutics, a UK based clinical stage specialty pharma company. Granules India, Greenko ZeroC collaborate for green molecule solutions. UniQure licenses gene therapy from Apic Bio. Sol-Gel acquires patidegib rights from PellePharm. Nogra Pharma out-licenses acne asset to Torii. Orna Therapeutics inks collaboration with Simnova on next-gen RNA technology in China. Nimble Therapeutics expands partnership with Genentech. Leap Therapeutics acquires Flame Biosciences through merger deal. Amolyt Pharma inks research and option deal with XOMA.

Updates at Aagami:

Aagami completed a very fruitful JPM week and Biotech Showcase 2023 in San Francisco (January 9–11) with over 40 one-on-one strategic meetings with decision makers in Biotech, Pharma and Medtech. Aagami celebrating 20 years in business. As a part of its 20th Anniversary year, Aagami will offer special benefits and discounts to its clients up until 31st March 2023.

INFOCUS: Select opportunities available at Aagami:

For Partnering/Licensing/ Investment: Licensing/Co-development: Easy to apply world’s First Transdermal Tizanidine Patch for the Management of Spasticity. Impressive Phase 1 results. Ready to initiate Phase 2. Lidocaine 10% Topical Patch; NDA approval expected in September 2023. (Licensing for US available). Made using Proprietary drug formulation technology, ILTS® (Ionic Liquid Transdermal Technology). Indication: the treatment of PHN (postherpetic neuralgia) Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships. A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. An unmet need for treating Bacterial Dysentery. Seeking funding/licensing/co-development partnerships. For Acquisition: Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.